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Objectives: To investigate whether, apart from effects of patient- and disease-related factors, psychosocial factors have
additional effects on disease activity; and which factors are most inﬂuential during the ﬁrst year of treatment in early
rheumatoid arthritis (RA).
Method: The study assessed 15 month follow-up data from patients in tREACH, a randomized clinical trial comparing
initial triple disease-modifying anti-rheumatic drug therapy to methotrexate monotherapy, with glucocorticoid bridging in
both groups. Patients were evaluated every 3 months and treated to target. Associations between Disease Activity Score
(DAS) at 3, 9, and 15 months and psychosocial factors (anxiety, depression, fatigue, and coping with pain) at the previous
visit were assessed by multivariable linear regression correcting for demographic, clinical, and treatment-related factors.
Results: At 3, 9, and 15 months of follow-up, 265, 251, and 162 patients, respectively, were available for analysis.
Baseline anxiety and coping with pain were associated with DAS at 3 months; coping with pain at 6 months was
associated with DAS at 9 months, and fatigue at 12 months with DAS at 15 months. Psychosocial factors were
moderately correlated. Effects on DAS were mainly due to tender joint count and global health.
Conclusion: Psychosocial factors have additional effects on DAS throughout the ﬁrst year of treatment in early RA. A
change was observed from anxiety and coping with pain at baseline being associated with subsequent DAS towards
fatigue being associated with subsequent DAS at 12 months. Owing to the explorative nature of this study, more
research is needed to conﬁrm this pattern.
Rheumatoid arthritis (RA) is a common autoimmune
disease and is associated with progressive disability,
early death, and socio-economic costs (1). Disease pro-
gression can be tackled by early treatment with disease-
modifying anti-rheumatic drugs (DMARDs), using tightly
controlled and treat-to-target strategies (2, 3). This target
has been proposed in guidelines as remission or low
disease activity, which is commonly measured in clinical
practice by composite scores such as the Disease Activity
Score (DAS) and the Disease Activity Score based on 28-
joint count (DAS28) (4). Recently published studies show
that with this regimen a response rate of 40–80% can be
reached within 1 year (5, 6). Several patient and disease
characteristics, such as baseline disease activity (7, 8), age
(7, 9), and gender (7–9), have been reported that may
explain part of the variability in response rates. However,
a large part of the variability remains unexplained,
suggesting that other, unidentiﬁed, factors may be at
play as well. Recent interest has been directed towards
the inﬂuence of psychosocial factors. Several studies have
reported signiﬁcant associations between baseline levels
of anxiety and/or depression and subsequent DAS or
DAS components (10–12). However, the effects of
psychosocial factors after treatment has been initiated on
disease activity have not been extensively studied.
Knowing and understanding the effect of psychosocial
factors underlying disease activity and treatment response
could provide important information for selection of
therapy, evaluation of response, and even targeted
psychological interventions aimed at optimizing patient
outcome (13).
In this study, we aimed to answer the following ques-
tions. (i) Is there, apart from effects of patient- and
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disease-related factors, an additional effect of psychoso-
cial factors on the disease activity during the ﬁrst year of
treatment in an early RA population? (ii) Which com-
pounds of psychosocial factors have the most inﬂuence
during the disease course?
Method
Study population
Fifteen-month follow-up data were used from the
tREACH cohort, for which a detailed description of
the inclusion criteria and protocol can be found in the
original tREACH paper (6). In brief, patients with
early arthritis (duration of complaints < 1 year) and a
high risk of developing persistent arthritis [score > 6
points on the Visser model (14)] were eligible. Of the
included patients, 97% fulﬁlled the American College
of Rheumatology/European League Against Rheuma-
tism (ACR/EULAR) 2010 criteria for RA (4). Patients
were randomized to the following induction treatment
strategies: triple DMARD therapy [iTDT; methotrexate
(MTX) 25 mg/week, sulphasalazine 2000 mg/day, and
hydroxychloroquine 400 mg/day] or MTX monother-
apy 25 mg/week (iMM). Both groups received brid-
ging therapy with glucocorticoids (GCs; triamcinolone
acetonide 80 mg or methylprednisolone 120 mg once
by intramuscular injection or oral prednisone 15 mg
for 4 weeks, thereafter tapered by 5 mg/week). Patients
were evaluated every 3 months. In cases where the
DAS was > 2.4, patients were switched to a tumour
necrosis factor blocker combined with MTX 25 mg/
week. If sustained remission (DAS < 1.6 at two con-
secutive visits) was achieved, medication was tapered
according to protocol. Detailed information on the
medication scheme can be found in the original
tREACH paper (6).
This study was approved by the medical ethics com-
mittee of the Erasmus Medical Center, Rotterdam, The
Netherlands.
Outcomes
Outcomes were the DAS at 3, 9, and 15 months of
follow-up.
Psychosocial factors
Psychosocial factors, measured at baseline and 6 and
12 months of follow-up, included coping with pain, anxiety
and depression, and fatigue, as explained in more detail
below.
Coping with pain. Coping with pain was measured by the
Coping with Rheumatic Stressors (CORS) questionnaire.
The list contains eight questions about coping with pain
(Cronbach’s alpha 0.88). Scores range from 8 to 40 (15).
Anxiety and depression. The Hospital Anxiety and
Depression Scale (HADS) was used to measure anxiety
and depression. The scores for anxiety and depression
range from 0 to 21, with higher scores indicating
symptoms related to more anxiety or depression (16).
Fatigue. Fatigue was assessed using the Fatigue
Assessment Scale (FAS). Questions were asked about the
patient’s fatigue status. The score ranges from 10 to 50,
with higher scores indicating higher levels of fatigue (17).
Demographic, disease-related, and treatment-related factors
Age, gender, rheumatoid factor (RF), and anti-citrulli-
nated protein (ACPA) status were assessed at baseline.
For this study, initial treatment strategy was included as
a binary variable, indicating MTX monotherapy with
GC bridging (coded 1) versus initial triple DMARD
therapy with either oral or intramuscular GC bridging
(coded 0). At follow-up visits, medication increase was
deﬁned as a dose increase or a switch to other medica-
tion. Medication decrease was deﬁned as a dose decrease
or discontinuation of medication. Medication increase
and decrease were also included as binary variables.
Statistical analyses
Missing data. In those patients with an available
outcome DAS, missing values in covariates at the
previous visit (see supplementary Table S1) were
completed using multiple imputation with chained
equations (mi impute chained procedure in STATA).
Given that the largest missing rate observed was 42.3%
(supplementary Table S1), a number of m = 50
imputations was chosen, taking into consideration the
rule of thumb that the number of imputations should at
least be equal to the percentage of incomplete cases (18).
To avoid bias, imputation models were constructed such
that all variables used in the analysis models were
included in the imputation models (18). Before
imputation, continuous variables were transformed to
normality using the ‘nscore’ package for STATA (19)
and transformed back to their original scale afterwards,
ensuring that imputed values could not lie outside the
observed data range (19). The complete speciﬁcation of
imputation models can be found in Supplementary ﬁle S2.
Analyses. Multivariable linear regression analyses were
performed for psychosocial factors, measured at baseline
and 6 and 12 months of follow-up, on outcome DAS at
3, 9, and 15 months of follow-up, respectively, and
correcting for demographic, disease-related, and treatment-
related factors.
First, DAS was regressed against each individual psy-
chosocial factor, controlling for DAS and medication
change at the previous visit and the baseline factors
age, gender, RF, and ACPA positivity. Then, a full
2 TM Kuijper et al
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model was built containing all four psychosocial factors
together and controlling for the same factors. Backward
elimination was performed on the full model until
remaining psychosocial factors were signiﬁcant. Statis-
tical analyses were performed using STATA 14.1 (Stata-
Corp, College Station, TX, USA) and p values < 0.05
were considered statistically signiﬁcant.
Results
In total, 281 patients were available for analysis, 161 of
whom had outcome DAS available at all three visits
(completers). Overall, the mean age was 53 years and
190 (68%) were female (Table 1). Mean baseline DAS
was 3.36 and 95% fulﬁlled the ACR/EULAR 2010
criteria for RA (6) (Table 1). Completers and non-com-
pleters were similar with respect to baseline characteri-
stics, except for a slightly higher percentage of
completers being RF positive and fulﬁlling the ACR/
EULAR 1987 criteria (Table 1).
Association after 3 months of treatment
Analyses of each psychosocial factor individually,
correcting for age, gender, RF, ACPA, and baseline
DAS, revealed that higher levels of anxiety, coping
with pain, and depression were associated with a
higher DAS at 3 months of follow-up. After applying
backward elimination on the full model, anxiety and
coping with pain were independent predictors for DAS
at 3 months of follow-up. In sensitivity analysis by
bootstrap samples, anxiety and coping with pain were
selected in 65.3% and 56.7% of samples, whereas
depression and fatigue were selected in < 15% of
samples (Table 2).
Association after 9 months of treatment
In the per-factor analysis of psychosocial factors, cor-
recting for age, gender, RF, ACPA, and DAS at
6 months, coping with pain was associated with DAS
at 9 months and fatigue showed a borderline signiﬁcant
association. After backward elimination, coping with
pain remained as a signiﬁcant predictor for DAS at
9 months of follow-up. In sensitivity analyses on boot-
strap samples, coping with pain was selected in 59.2% of
samples and fatigue in 20.4% of samples.
Association after 15 months of treatment
Per-factor analysis showed that only fatigue was signiﬁ-
cantly associated with DAS at 15 months when correcting
for age, gender, RF, ACPA, and DAS at 12 months. This
was also the case in the backward elimination model. In
sensitivity analyses on bootstrap samples, fatigue was
Table 1. Baseline characteristics.
Characteristics
All patients
(n = 281)
Completers
(outcome DAS available
at 3, 9, and 15 months)
(n = 161)
Non-completers
(outcome DAS missing
at 3, 9, or 15 months)
(n = 120) p*
Demographic
Age (years) 53 (14) 53 (14) 53 (14) 0.981
Gender (female) 190 (68) 104 (65) 86 (72) 0.210
Disease-related
Duration of complaints (days) 166 ± 91 168 ± 87 164 ± 97 0.662
RF-positive 228 (81) 138 (86) 90 (75) 0.023
ACPA-positive 226 (80) 133 (83) 93 (78) 0.286
Fulﬁlling ACR/EULAR 1987 criteria 189 (67) 118 (73) 71 (59) 0.013
Fulﬁlling ACR/EULAR 2010 criteria 267 (95) 154 (96) 113 (94) 0.571
DAS 3.36 ± 0.96 3.39 ± 0.97 3.33 ± 0.95 0.648
HAQ 1.00 ± 0.66 0.97 ± 0.65 1.03 ± 0.67 0.496
tSvHs 0 (0–0) 0 (0–0) 0 (0–0) 0.266†
Anxiety (HADS) 5.8 ± 3.7 5.8 ± 3.9 5.8 ± 3.5 0.861
Depression (HADS) 4.6 ± 3.4 4.5 ± 3.4 4.6 ± 3.4 0.843
Fatigue (FAS) 22.2 ± 7.0 22.6 ± 7.3 22.0 ± 6.8 0.542
Coping with pain (CORS) 15.5 ± 5.2 16.2 ± 5.2 15.0 ± 5.1 0.058
Data are shown as n (%), mean ± sd, or median (interquartile range).
*Differences between completers and non-completers were tested. Student’s t-test and Pearson’s chi-squared test were used as
appropriate, unless speciﬁed otherwise.
†Wilcoxon rank-sum test.
RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; ACR, American College of Rheumatology; EULAR, European
League Against Rheumatism; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; tSvHs, total Sharp van der
Heijde score; HADS, Hospital Anxiety and Depression Scale; FAS, Fatigue Assessment Scale; CORS, Coping with Rheumatic
Stressors.
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selected in 51.5% of instances, whereas other psychosocial
factors were selected in < 20% of samples.
Correlation between psychosocial factors
Pearson correlations between psychosocial factors for
each time-point are shown in supplementary Table S3.
In particular, anxiety, depression, and fatigue were
highly correlated with each other, with correlation coef-
ﬁcients around 50–70%. Coping with pain shows mod-
erate correlations with the other factors, with correlation
coefﬁcients around 25–50%.
Course over time of psychosocial factors
To gain further insight, development over time of psy-
chosocial factors was investigated (supplementary
Figure S4). All scores showed signiﬁcant decreases at
6 and 12 months with respect to baseline scores, except
for coping with pain at 6 months.
Associations between psychosocial factor and DAS
components
To evaluate which DAS components are associated with
psychosocial factors at the previous visit, linear and
zero-inﬂated negative binomial regression models were
performed (Table 3). The most signiﬁcant associations
were observed for the subjective components Ritchie
Articular Index (RAI) and Global Health (GH). Some
signiﬁcant associations for objective components were
also observed: higher levels of baseline coping with pain
were associated with both a higher 44-joint swollen joint
count (SJC44) and erythrocyte sedimentation rate (ESR)
at 3 months, while higher levels of fatigue at 6 months
were associated with lower levels of ESR at 9 months
(Table 3).
Discussion
In this longitudinal study of RA patients starting with
DMARD therapy, we found that psychosocial factors
were independently associated with DAS at the next
3 monthly visit during the ﬁrst year of follow-up. The
psychosocial factors associated with DAS changed over
time: coping with pain and anxiety inﬂuenced the dis-
ease activity in the ﬁrst 3 months, but anxiety no longer
appeared to play a role after 9 months of treatment. In
the phase where disease activity is low, only fatigue
played a role. Although speculative, the change
observed may indicate a shift in the relative importance
of psychosocial factors over the course of disease in
newly diagnosed patients with RA. In the ﬁrst months
after diagnosis, when disease is still active and optimal
treatment effect has not yet been achieved, it is imagin-
able that anxiety and coping with pain play a more
pronounced role, especially by affecting the more sub-
jective components of DAS RAI and GH. Later on,
when disease is under control and patients have adapted
to living with the disease, fatigue could be more in the
foreground. However, it should be noted that the
Table 2. Multivariable linear regression analysis of psychosocial factors at baseline and 6 and 12 months on Disease Activity Score
(DAS) at 3, 9, and 15 months, respectively.
Multivariable,
per factor
Multivariable,
full
Multivariable,
after backward elimination
Beta p 95% CI Beta p 95% CI Beta p 95% CI %*
DAS 3 months (n = 265)
Anxiety (T0) 0.043 0.005 0.013 to 0.073 0.037 0.050 −0.000 to 0.075 0.037 0.015 0.007 to 0.067 65.3
Depression (T0) 0.034 0.037 0.002 to 0.066 −0.001 0.963 −0.044 to 0.042 11.4
Fatigue (T0) 0.015 0.070 −0.001 to 0.031 0.001 0.935 −0.189 to 0.020 7.8
Coping with pain (T0) 0.028 0.012 0.006 to 0.051 0.024 0.051 −0.000 to 0.048 0.024 0.036 0.002 to 0.046 56.7
DAS 9 months (n = 251)
Anxiety (T6) 0.017 0.217 −0.010 to 0.044 0.004 0.822 −0.034 to 0.043 12.3
Depression (T6) 0.023 0.115 −0.006 to 0.052 0.001 0.975 −0.046 to 0.048 12.6
Fatigue (T6) 0.014 0.060 −0.001 to 0.028 0.006 0.602 −0.015 to 0.026 20.4
Coping with pain (T6) 0.025 0.016 0.005 to 0.045 0.021 0.081 −0.003 to 0.044 0.025 0.016 0.005 to 0.045 59.2
DAS 15 months (n = 162)
Anxiety (T12) 0.012 0.459 −0.020 to 0.043 −0.013 0.525 −0.055 to 0.028 11.6
Depression (T12) 0.028 0.095 −0.005 to 0.060 0.011 0.669 −0.040 to 0.062 18.2
Fatigue (T12) 0.019 0.020 0.003 to 0.035 0.017 0.179 −0.008 to 0.041 0.019 0.020 0.003 to 0.035 51.5
Coping with pain (T12) 0.019 0.102 −0.004 to 0.041 0.007 0.619 −0.019 to 0.033 13.4
All analyses are corrected for age, gender, rheumatoid factor, anti-citrullinated protein antibodies, initial treatment group, medica-
tion change at the previous visit, and DAS at the previous visit.
*Selection rate of psychosocial factors after applying backward elimination in bootstrap samples.
The ﬁgures in bold type indicate a signiﬁcant association for the covariate with the outcome.
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psychosocial factors that we investigated are highly cor-
related, which is in line with previous studies that found
that symptoms of anxiety and depression often co-occur
in RA patients (20). Therefore, care should be taken in
drawing deﬁnite conclusions with respect to the impor-
tance of one factor over another, and no deﬁnite conclu-
sions of a change in relative importance should be drawn
based on the results of this study alone. However, over-
all, our results do suggest that psychosocial factors in
general appear to play an additional role in explaining
responses to treatment during the entire ﬁrst year of
follow-up.
Several previous studies have investigated the effects
of psychosocial factors on DAS at subsequent visits. In a
secondary analysis of a clinical trial in early RA, Matc-
ham et al. (12) found that both baseline and persistent
symptoms of depression/anxiety symptoms, measured
on a combined scale of the EuroQol 5 Dimensions
(EQ-5D), were associated with increased DAS28 scores
over the ﬁrst 2 years of follow-up. This is partly in
agreement with our study, in which we found both base-
line anxiety and depression scores to be associated with
higher DAS at 3 months of follow-up, but not at later
time-points (12). Differences may, at least in part, be
explained by the use of a different instrument to measure
depression/anxiety symptoms and differences in analyti-
cal approach (linear mixed model averaging outcome
over time) (12).
Previous studies have also looked into which compo-
nents of the DAS are associated with psychosocial distress.
In the COMET trial, signiﬁcant associations between
depression and both subjective (i.e. tender joint count and
general health) and objective (i.e. swollen joint count and
ESR) components of DAS were observed (10), whereas
Matcham et al. only found associations for subjective
components of DAS (11, 12). Regarding our own results,
most associations are observed for the subjective compo-
nents (Table 3). In patients with high levels of psychosocial
distress, this may lead to overtreatment and higher costs if
rheumatologists perform DAS-steered treatment without
recognizing that the increased DAS is based on subjective
components rather than inﬂammation. We therefore
recommend that rheumatologists be aware of psychosocial
distress and its impact on DAS when adjusting therapy.
Several strengths and limitations of this study
should be noted. Strong points include the fact that
data were used from a prospective randomized clinical
trial on early RA patients who were treated to target
according to current guidelines (2, 3). Although not
powered for this analysis, the sample size appears to
be adequate for the scope of this analysis. The number
of missing values in predictor variables was small at
baseline, but increased at follow-up visits (supplemen-
tary Table S1). To increase power and avoid bias in
the analysis, we used multiple imputation to complete
missing covariates for those patients having an out-
come DAS available at the subsequent visit. None-
theless, the complete case analysis for patients
without missing covariates showed similar results
(supplementary Table S5). Few studies have assessed
Table 3. Association of psychosocial factors at baseline and 6 and 12 months on Disease Activity Score (DAS) components at 3, 9,
and 15 months, respectively, by zero-inﬂated negative binomial regression or linear regression.
SJC44* ln ESR† RAI* GH†
Beta p Beta p Beta p Beta p
DAS 3 months (n = 252)
Anxiety (T0) 0.006 0.723 −0.005 0.752 0.033 0.031 1.728 <0.001
Depression (T0) −0.002 0.895 0.016 0.353 0.008 0.631 1.687 <0.001
Fatigue (T0) 0.014 0.129 −0.004 0.648 0.008 0.361 0.726 0.001
Coping with pain (T0) 0.046 <0.001 0.030 0.008 0.021 0.055 0.121 0.677
DAS 9 months (n = 214)
Anxiety (T6) 0.004 0.859 −0.014 0.469 0.012 0.508 1.689 <0.001
Depression (T6) −0.020 0.371 −0.024 0.226 0.026 0.159 2.199 <0.001
Fatigue (T6) −0.002 0.821 −0.024 0.011 0.025 0.003 1.045 <0.001
Coping with pain (T6) −0.015 0.379 −0.015 0.275 0.029 0.025 0.900 0.008
DAS 15 months (n = 141)
Anxiety (T12) 0.008 0.817 −0.010 0.636 0.020 0.458 0.499 0.334
Depression (T12) −0.041 0.247 0.013 0.547 0.041 0.078 0.717 0.172
Fatigue (T12) 0.001 0.952 −0.008 0.494 0.039 0.002 0.478 0.083
Coping with pain (T12) 0.017 0.462 −0.011 0.514 0.063 <0.001 −0.158 0.686
All analyses are corrected for age, gender, rheumatoid factor, anti-citrullinated protein antibodies, initial treatment group, medica-
tion change at the previous visit, and DAS at the previous visit.
*Zero-inﬂated negative binomial regression.
†Linear regression.
SJC44, 44-joint swollen joint count; ln, natural logarithm; ESR, erythrocyte sedimentation rate; RAI, Ritchie Articular Index; GH, Global Health.
The ﬁgures in bold type indicate a signiﬁcant association for the covariate with the outcome.
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the additional effect of psychosocial factors on DAS
and, to our knowledge, no previous studies have
assessed them at speciﬁc time-points after baseline.
Several limitations should be mentioned as well. By the
multiple imputation procedure, we completed missing
covariates for those patients having an outcome DAS
available at the subsequent visit. However, this does not
take into account potential selection bias by patients com-
pletely dropping out from the study over time. Although
selective dropout cannot be ruled out, patients with com-
plete and incomplete follow-up were similar with respect
to most baseline characteristics (Table 1). Furthermore, in
a secondary analysis in selected patients with complete
follow-up only (supplementary Table S7), except for base-
line depression and coping with pain in relation to DAS
after 3 months, which could be related to the smaller
sample size, all psychosocial factors identiﬁed in the
main analysis (Table 2) maintained signiﬁcance.
Data were used from a randomized clinical trial that was
not designed for the purpose of these analyses. As the
clinical trial setting differs from clinical practice, it cannot
be ruled out that by selection bias different effects would
have been observed if a similar study were performed in a
clinical practice setting. Another potential limitation is the
issue of multiple testing. Because of the explorative nature
of the study and commonly available solutions such as the
Bonferroni method tend to be highly conservative, no
formal methods were applied to account for this. Although
under the null hypothesis it is still highly unlikely that ﬁve
out of 12 signiﬁcant associations (multivariable per-factor
analysis, Table 2) would be obtained by chance alone, it
cannot be ruled out that some of these were due to chance.
Conclusion
We found that psychosocial factors affect subsequent
DAS during the ﬁrst year of follow-up in patients newly
diagnosed with RA. A change in pattern was observed
from anxiety and coping with pain being associated with
subsequent DAS at baseline towards fatigue being asso-
ciated with subsequent DAS at 12 months of follow-up.
Owing to correlation between psychosocial factors and the
explorative nature of this study, more research is needed to
conﬁrm this pattern.
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